Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

ASCO 2025 showcases breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the ...

Oncolytics Biotech reveals promising survival data for pelareorep, an innovative immunotherapy, showing significant benefits ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate cancer.